⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMRX News
Immuneering Corporation Class A Common Stock
Form 8-K
sec.gov
IMRX
Immuneering Appoints Andrew Gengos as Chief Financial Officer
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
globenewswire.com
IMRX
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
IMRX
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
globenewswire.com
IMRX